Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery


Adult Primary Hepatocellular Carcinoma | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer

What is the purpose of this trial?

This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how
well they work compared with chemoembolization alone in treating patients with liver cancer
that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin
hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels
near the tumor and then blocking the blood flow to allow a higher concentration of the drug
to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether giving chemoembolization together with sorafenib tosylate is more effective than
chemoembolization alone in treating patients with liver cancer.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
October 2009
Last Updated:
November 20, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01004978